2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNADouble-strandedd Breaks and Induces Regression in Preclinical Models of Human Cancer

Ottawa, ON, Canada (UroToday.com) Insulin-like growth factor-1 receptor (IGF-1R) is expressed in many tumors. This study reports on the use of Ac225 labeled FPI-1434 for treating three types of tumors in mice. FPI-1434 is a commercial humanized monoclonal antibody targeting the IGF-1R receptor. Immunodeficient mice were inoculated with either Colo-205 (colorectal), A549 (non-small cell lung), or LNCaP (prostate) xenografts.

Colo-205 mice were treated at doses of 0.05, 0.2, and 0.4 μCi. Reduction of tumor volume was seen in all doses. LNCap and A549 showed similar results after a single dose. DNA double-strand breaks were studied with yH2AX. Phase, I trials with FPI-1434,4 will begin soon.


Presented by: Eric Burak, PhD, Fusion Pharmaceuticals, Hamilton, Ontario, Canada

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada